Recursion Pharmaceuticals, Inc..
RXRX.US | Research and experimental development on natural sciences and engineering
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging its Recursion OS platform to discover, develop, and deliver medicines that expand human health. The Recursion OS platform combines automation, artificial intelligence, machine learning, and biological data to accele...Show More
Better Health for All
0
Insufficient evidence to determine a value score for Recursion Pharmaceuticals, Inc. regarding Better Health for All. No articles or relevant information found. A neutral score of 0 is assigned.
Materiality Analysis: Company Summary: Recursion Pharmaceuticals is a clinical-stage biotechnology company focused on drug discovery through technological innovation. They develop treatments for cerebral cavernous malformation, neurofibromatosis type 2, familial adenomatous polyposis, Clostridioides difficile infection, and certain cancers. They collaborate with Bayer, Roche, Genentech, Takeda, and academic institutions. Their operations are primarily based in the United States.
Peer Comparison: Compared to other clinical-stage biotech companies, Recursion's focus on repurposing existing drugs and using AI for drug discovery is relatively unique. Many peers focus on novel molecule development. Their commitment to addressing rare diseases aligns with industry trends, but their AI-driven approach may give them an edge in efficiency.
Materiality Assessment: The business model is fundamentally supportive of Better Health for All, with a high level of materiality.
Detailed Rationale: Recursion's core business directly addresses Better Health for All by developing treatments for various diseases, including rare and genetic disorders. Their focus on repurposing existing drugs and using AI to accelerate drug discovery could potentially lead to more affordable and accessible treatments. Their pipeline targets conditions with significant unmet medical needs. Collaborations with major pharmaceutical companies could facilitate wider distribution and access to their drugs if approved. While the company is still in the clinical stage and faces the inherent risks of drug development, their mission and pipeline strongly align with improving health outcomes. Their focus on data-driven drug discovery could also lead to more personalized and effective treatments.
Value Interaction Notes: N/A
Scoring Boundary Flags: A score in the lowest range would be illogical, given the company's explicit focus on developing treatments for diseases. A score below 4 would not be appropriate.
Fair Money & Economic Opportunity
0
Recursion Pharmaceuticals, Inc. is a biotechnology company focused on drug discovery and development, not a financial institution. The company does not offer lending, deposit, or other financial services to consumers. Therefore, all KPIs related to financial products, pricing, fees, lending, customer financial outcomes, and financial literacy are not applicable to its core business model. While the company engages in various diversity, equity, and inclusion initiatives, supports startups through Altitude Lab,
1
and provides employee stock-based compensation,
2
these activities do not fall under the scope of providing fair financial services or economic opportunity in the context of the rubric's definition for financial institutions.
Fair Pay & Worker Respect
-10
The company's global employee rating on Glassdoor is 3.7 out of 5 stars, with 69% of employees recommending working there and 86% CEO approval.
1
This overall rating translates to approximately 74% satisfaction, which aligns with a healthy workplace culture. However, reviews frequently mention concerns about work-life balance, management struggles, and frequent layoffs, which are cited as a significant concern.
2
While no specific turnover rate is provided, the mention of frequent layoffs and a demanding work environment suggests a potential issue with retention.
3
Fair Trade & Ethical Sourcing
0
No specific, quantifiable evidence was found in the provided articles for any of the KPIs under the 'Fair Trade & Ethical Sourcing' value. While a 'Supplier Code of Conduct' was launched in 2022 and a 'Vendor Expectations Manual' exists,
1
there is no data on the percentage of spend covered by fair-trade certifications, supplier audit frequency, substantiated forced or child labor incidents, traceability coverage, remediation speed, the percentage of supplier contracts with enforceable ethical clauses, the share of spend on high-risk materials, or the current percentage of procurement budget directed to diverse suppliers. Plans and objectives for supplier diversity were mentioned, but not current achievements.
2
Honest & Fair Business
-10
Recursion Pharmaceuticals has a comprehensive Whistleblower Policy, adopted in February 2021, which allows for confidential and anonymous complaints via a 24/7 third-party secure web portal (EthicsPoint) and hotline.
1
The policy prohibits retaliation and is overseen by the Audit Committee.
2
The company also has a Global Anti-Bribery and Anti-Corruption Policy, adopted in March 2021, with a zero-tolerance stance on bribery and facilitation payments.
3
This policy requires annual certifications from all team members, risk-based due diligence screening for third-party representatives, and detailed, accurate record-keeping.
4
However, the company disclosed a material weakness in internal control over financial reporting as of June 30, 2024, which required remediation actions.
5
While the company uses a third-party for its whistleblower reporting channels, the extent of independent verification of other ethical claims is limited to risk-based due diligence screening on third-party representatives.
6
Kind to Animals
-60
Recursion Pharmaceuticals conducts pre-clinical studies on animals to assess drug safety, explicitly stating they 'exploit animals for product testing'.
1
The company uses approximately 1,000 digital animal enclosures (vivariums) for animal studies.
2
While the company develops and uses a deep learning model (InVivoPrint V1 - IVP-1) to analyze animal data for liabilities, this is for analyzing existing animal data rather than replacing animal testing.
3
Recursion is heavily invested in AI-drug discovery, and its stock surged following the FDA's move to phase out animal testing in favor of AI-based computational models.
4
However, there is no evidence of specific R&D budget allocation to animal-free technologies, nor participation in multi-stakeholder initiatives for animal-free standards, or active engagement in animal welfare policy improvement.
5
No War, No Weapons
0
The company's core business is pharmaceuticals.
1
and the provided articles do not contain any specific information regarding revenue from arms or defense contracts, R&D investment in dual-use technologies, or sales to embargoed regimes. There is no evidence of peacebuilding initiatives, a conflict divestment policy, or board oversight of defense activities. While the company had total lobbying expenditures of $100,000 in 2025,
2
there is no information on the proportion of this spending allocated to supporting or opposing arms-control legislation. Similarly, there is no data on humanitarian procurement compliance, human rights due diligence in conflict areas, Arms Trade Treaty compliance, or AI military safeguards. The articles do not mention any ethical red lines related to weapons, exposure to controversial weapons, war-risk audit results, or annual reviews of conflict-related partners. There is also no information on divestment from defense assets, conflict minerals, peace technology investment, or procurement from conflict zones.
Planet-Friendly Business
-50
In 2023, Recursion Pharmaceuticals reported Scope 1 GHG emissions of 854 metric tons CO2e and Scope 2 GHG emissions (market-based) of 1,474 metric tons CO2e, totaling 2,327 metric tons CO2e.
1
The company initiated assessment of Scope 3 emissions in 2023 and calculated them for the first time in 2024.
2
Recursion aims to achieve net-zero greenhouse gas emissions by 2030 for Scope 1 and 2.
3
The company plans to offset 100% of energy usage at its Salt Lake City headquarters with Renewable Energy Credits in 2024, and 100% of electricity consumed by its BioHive-1 supercomputer was generated from renewable sources in 2023.
4
The Toronto office is designed to meet Toronto Green Standard requirements, and the London office meets BREEAM 'Excellent' rating requirements, but a low percentage of overall facilities are certified.
5
In 2023, the company recycled 8.14 tons of waste and composted 5.85 tons.
6
No environmental compliance violations were reported.
7
Recursion's facilities undergo an environmental assessment at least annually.
8
The company aligned its climate-related risk management approach with the TCFD framework in 2023, and its ESG report is guided by TCFD.
9
However, climate scenario analysis has not been formally completed.
10
A Supplier Code of Conduct was launched in 2022, and the company is exploring a program to engage key suppliers around measurement and target setting.
11
Respect for Cultures & Communities
10
Recursion Pharmaceuticals has 13 formal partnerships with various organizations, including Discovery Gateway, Salt Lake Economic Development Council, BioHive, University of Utah’s PIVOT Center, Alliance for Artificial Intelligence in Healthcare (AAIH), National Organization for Rare Diseases (NORD), RareX, Children’s Tumor Foundation, Alliance to Cure, Desmoid Tumor Foundation, Rare Utah, Rare and Undiagnosed Network, and Bright Horizons.
1
The company has reported no cultural appropriation incidents.
2
Recursion's operations do not appear to impact cultural contexts, thus no specific cultural impact assessment protocol or FPIC processes are applicable. The company provides a whistleblower policy with a confidential and secure web portal and reporting hotline available 24/7, which serves as a standard grievance mechanism.
3
Safe & Smart Tech
0
No evidence available to assess Recursion Pharmaceuticals, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
-40
In 2022, Recursion Pharmaceuticals achieved a waste diversion rate of 45.76%, diverting 8.76 tons of waste (mixed recyclables, glass, food composted) out of 19.14 tons generated.
1
The company has implemented several waste reduction initiatives, including a detailed Hazardous Waste Policy with in-house treatment of biological hazardous waste, lab recycling for noncontaminated supplies, and office waste management for glass, plastics, paper, and batteries.
2
Recursion conducts annual environmental assessments for all its facilities.
3
The company reported zero waste disposal violations in the past three years.
4
Recursion has set a company-wide target to become net-zero for greenhouse gas emissions by 2030.
5
In 2022, the company launched a Supplier Code of Conduct, which includes waste-related requirements for all tier-1 suppliers.
6